About
Eric Morgen, M.D., is co-founder, COO, and a director of BioAge Labs, a clinical-stage biotechnology company developing therapies that target the biology of aging, especially metabolic disease and obesity. He previously served on the faculty at the University of Toronto and has published in biomarker discovery, computational biology, aging, and diagnostic medicine. He also serves as a director of the Alliance for Longevity Initiatives (A4LI), linking him to the longevity-policy ecosystem.
Areas of interest
longevityaging biologybiotechdrug developmentobesity therapeuticsmetabolic diseaselife scienceshealthtechAI in life scienceslongevity policy & advocacy